Your shopping cart is empty!
Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
Catalog: | HY-B0236 |
Brand: | MCE |
CAS: | 60-32-2 |
MDL | MFCD00008238 |
---|---|
Molecular Weight | 131.17 |
Molecular Formula | C6H13NO2 |
SMILES | O=C(O)CCCCCN |
6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen . 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders [1] [2] .
6-Aminocaproic acid (20-180 μg/mL) inhibits fibrinolysis in plasma of Asian elephants, with an effective concentration of 61.5 μg/mL
[2]
.
6-Aminocaproic acid can be used as a hydrophobic linker to improve near-infrared fluorescence imaging and photothermal cancer therapy of PEGylated indocyanine green
[4]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
6-Aminocaproic acid (20-100 mg/kg; a single p.o.) inhibits fibrinolysis at all doses tested in dogs
[3]
.
6-Aminocaproic acid (20-100 mg/kg; a single p.o.) is rapidly absorbed (T
max
=1 h) and eliminated rapidly in dogs
[3]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT01965730 | University of Pennsylvania |
Aortic Disease
|
January 2013 | Early Phase 1 |
NCT01391182 | Mayo Clinic |
Degenerative Joint Disease|Osteoarthritis
|
July 2011 | Not Applicable |
NCT02074436 | Emory University |
Hematological Malignancies|Thrombocytopenia
|
May 23, 2014 | Phase 2 |
NCT01873768 | Miller Orthopedic Specialists|CHI Health Mercy Hospital|Creighton University Medical Center |
Osteoarthritis
|
January 2014 | Phase 4 |
NCT05291312 | Assiut University |
Adenoid Hypertrophy
|
May 1, 2022 | Not Applicable |
NCT00320619 | National Heart, Lung, and Blood Institute (NHLBI) |
Scoliosis|Kyphosis|Lordosis|Spondylitis|Spinal Stenosis
|
September 2000 | Not Applicable |
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
H 2 O : ≥ 50 mg/mL ( 381.18 mM )
DMSO : 1 mg/mL ( 7.62 mM ; Need ultrasonic)
* "≥" means soluble, but saturation unknown.
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 7.6237 mL | 38.1185 mL | 76.2369 mL |
5 mM | 1.5247 mL | 7.6237 mL | 15.2474 mL |
10 mM | 0.7624 mL | 3.8118 mL | 7.6237 mL |
Add each solvent one by one: PBS
Solubility: 25 mg/mL (190.59 mM); Clear solution; Need ultrasonic
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.